01 March 2005 : Original article
Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson Disease
Alexander M. GobermanMed Sci Monit 2005; 11(3): CR109-116 :: ID: 15386
Abstract
Background: Research has found that non-speech motor defi cits in Parkinson Disease (PD) can be consistently improved by levodopa medications and surgical treatment, but that speech and voice are only
partially responsive to treatment. This has led to the assertion that speech is an axial (non-peripheral) feature of PD, along with other features that are only partially responsive to treatment (e.g., postural stability and gait). The current study tested this assertion via examination of the relationship between multiple measures of speech production and multiple measures of non-speech movement in individuals with PD.
Material/Methods: Nine individuals with idiopathic PD were studied, and all participants were taking levodopa-carbidopa medication. Motor performance was examined using the motor portion of the Unifi ed
Parkinson’s Disease Rating Scale, and speech was examined via acoustic analysis of phonation, articulation, and prosody.
Results: Seven of sixteen speech acoustic measures (F[sub]o[/sub]SD in vowels, F2 slope for /u/ and /æ/, F[sub]o[/sub]SD in reading, articulation rate in monologue, and percent pause in reading and monologue) were signifi - cantly correlated with non-speech movements. Results suggested that speech measures are correlated with both axial motor symptoms (e.g., gait, facial expression, posture, postural stability) and
non-axial motor symptoms (e.g., rest tremor, left and right bradykinesia, postural tremor).
Conclusions: It has been hypothesized that axial symptoms of PD are more purely dopaminergic, and non-axial symptoms are related to non-dopaminergic lesions. Therefore, the current results indicate that
certain speech defi cits in PD may result from dopaminergic lesions, while others appear to result from non-dopaminergic lesions.
Keywords: Carbidopa - pharmacology, Carbidopa - therapeutic use, Gait - drug effects, Motor Skills Disorders - complications, Aged, 80 and over, Antiparkinson Agents - therapeutic use, Carbidopa - therapeutic use, Deep Brain Stimulation, Gait - drug effects, Levodopa - therapeutic use, Motor Skills, Motor Skills Disorders - physiopathology, Parkinson Disease - physiopathology, Severity of Illness Index, Speech Acoustics, Time Factors
Editorial
01 March 2025 : Editorial
Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical TrialsDOI: 10.12659/MSM.948672
Med Sci Monit 2025; 31:e948672
In Press
Clinical Research
Inflammatory Biomarkers in Smokers: Implications for Ligamentum Flavum HypertrophyMed Sci Monit In Press; DOI: 10.12659/MSM.947508
Clinical Research
Balancing Image Quality and Iodine Intake: Insights from CT Spectral Imaging of the Portal VeinMed Sci Monit In Press; DOI: 10.12659/MSM.947391
Review article
Regulatory Efforts and Health Implications of Energy Drink Consumption by Minors in PolandMed Sci Monit In Press; DOI: 10.12659/MSM.947124
Review article
Current Trends and Innovations in Oral and Maxillofacial ReconstructionMed Sci Monit In Press; DOI: 10.12659/MSM.947152
Most Viewed Current Articles
17 Jan 2024 : Review article 7,216,875
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,406
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 27,844
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 22,117
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912